Developing novel ADC

immuno-therapeutics to

treat high need cancers

Lead program: Nectin-4-targeting ADC – with potential across a range of hard to treat cancers.

Linker technology and amanitin payload proprietary to Heidelberg Pharma designed to deliver higher efficacy, lower risk of side effects and ability to avoid tumor resistance.

Focus on hard to treat cancers by exploiting loss of POLR2A gene in 17p deletion tumors.

About Us

Read More >

Science

Read More >

Execution

Read More >

Partners

Read More >

Latest News

23/03/2020

Emergence Therapeutics to Attend Upcoming Conferences

Emergence Therapeutics, a new European biopharmaceutical company developing novel antibody drug conjugate (ADC) immuno-therapeutics to treat high need cancers, announces that Dr. Jack Elands, Chief Executive Officer of Emergence Therapeutics, will be attending the following upcoming conferences in 2020: Bio Europe Spring Date: March 23 – 25 Location: Virtual ASCO Date: May 29 – June...

View Article >
23/03/2020

Emergence Tx New Website Launch

Dr. Jack Elands, Chief Executive Officer of Emergence Therapeutics, to participate in Bio-Europe Spring digital event on 23-27 March Emergence Therapeutics, a new European biopharmaceutical company developing novel antibody drug conjugate (ADC) immuno-therapeutics to treat high need cancers, has launched its new company website. Emergence Therapeutics’ science is being harnessed to develop best- or first-in-class...

View Article >